KLHL2

Across TCGA pan-cancer cohorts, KLHL2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated KLHL2 data layer compared with 27 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher KLHL2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KLHL2 expression acts as an unfavorable survival marker.

CESC, LIHC, and COAD are the cancer types where KLHL2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	III,IV	0.068	0.756	<.001	12	view →
LIHC	OS	Median	III,IV	0.270	0.732	.021	9	view →
COAD	DFS	Median	III,IV	0.271	0.652	.022	7	view →
HNSC	OS	Median	II,III,IV	0.192	0.601	.028	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	III,IV	0.245	0.721	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

KLHL2–CESC (OS)

Open the CESC breakdown →